Adaptive Biotechnologies forecasted robust growth for its minimal residual disease (MRD) business in 2026, projecting at least 20% year‑over‑year revenue expansion driven by wider adoption of its ClonoSeq assay across indications and settings. Management cited rising test volumes, deeper penetration into community clinics, and expanding EMR integrations as drivers; the company expects to raise average selling price modestly through payor renegotiations. Adaptive also flagged growing use of MRD as a clinical endpoint in registrational trials as a revenue and service opportunity. The guidance signals strengthening commercial traction for blood‑based MRD testing and underscores MRD’s increasing role in oncology drug development and patient monitoring workflows.